期刊,中国神经再生研究（英文版） 2025年卷5期_国家学术搜索

国家学术搜索

登录注册

首页期刊导航|中国神经再生研究（英文版）

期刊信息/Journal information

中国神经再生研究（英文版）

中国康复医学会

主办单位：中国康复医学会

出版周期：旬刊

国际刊号：1673-5374

电子邮箱：bwb@nrronline.com

电　　话：024-23381085

邮政编码：110004

地　　址：沈阳1234邮政信箱

中国神经再生研究（英文版）/Journal Neural Regeneration ResearchCSCDCSTPCD北大核心SCI

查看更多>>SCI收录杂志！！！本刊为英文版杂志，以国际通用语言研究最前沿、最热点的神经再生问题。创刊起点高，评估论文研究成果的学术标准高，对论文语言表述水平的要求高。刊物宗旨： 2006年创刊，面向国际、立足国际，以办好一本国际神经再生学科界专家公认的专业性学术期刊为工作目标，主要发表神经再生领域基础及应用基础研究方面的学术文章。出版重点： 2009年本刊重点出版对神经损伤修复过程中原位神经干细胞以及移植的神经干细胞作用机制的研究，出版神经组织工程、神经退行性疾病组织形态学变化以及中医药对神经细胞、神经组织再生过程中生理、病理结构变化影响的相关研究文章。面向国际，立足国际，关注全球范围内具有创新性的抑制、促进或影响神经细胞、神经组织再生结构变化相关机制的研究，关注由此而发生的一系列功能变化及其相互关系。感兴趣神经解剖学、病理学、生理学、生物化学、药理学、免疫学、发育学等来自多学科、多层面的题材，感兴趣发表以基础实验性研究为主的揭示大脑皮质、海马、松果体、神经胶质细胞、脊髓神经元、周围神经元以及运动和感觉神经损伤与再生的研究原著，对有助于认识神经再生正常和异常机制的临床类文章，如罕见病例报告、调查分析等也可纳入范围。欢迎文章从理论假设、研究方法、模型制备、影像学技术等多个视角描述神经再生的相关特点，为读者提供该领域最有价值的学科进展信息及其最新的理论观点，增强对神经再生复杂机制、学说和病理发生过程的理解。一般文章2000-4000单词。非常注重出版时效。投稿15～30天编辑部采用随机盲法抽取国际评审专家审稿，符合采用标准的文章进入修稿程序，力求出版周期120～180天，以保证高质量优秀稿件抢先出版。收录情况：科学引文索引（SCI） 2006年被SCI引文库收录8篇 2008年1月至2008年7月被SCI收录文章188篇美国生物学文献数据库（BIOSIS）美国《化学文摘》（CA）荷兰《医学文摘库/医学文摘》（EM）波兰《哥伯尼索引》（IC）中国英文版科技期刊数据库(统计源期刊) 中国科学引文数据库（核心期刊） 2007年被CA收录247篇，被EM收录173篇

正式出版

收录年代

Stiffness-tunable biomaterials provide a good extracellular matrix environment for axon growth and regeneration

Ronglin HanLanxin LuoCaiyan WeiYaru Qiao...

1364-1376页

查看更多>>摘要：Neuronal growth,extension,branching,and formation of neural networks are markedly influenced by the extracellular matrix—a complex network composed of proteins and carbohydrates secreted by cells.In addition to providing physical support for cells,the extracellular matrix also conveys critical mechanical stiffness cues.During the development of the nervous system,extracellular matrix stiffness plays a central role in guiding neuronal growth,particularly in the context of axonal extension,which is crucial for the formation of neural networks.In neural tissue engineering,manipulation of biomaterial stiffness is a promising strategy to provide a permissive environment for the repair and regeneration of injured nervous tissue.Recent research has fine-tuned synthetic biomaterials to fabricate scaffolds that closely replicate the stiffness profiles observed in the nervous system.In this review,we highlight the molecular mechanisms by which extracellular matrix stiffness regulates axonal growth and regeneration.We highlight the progress made in the development of stiffness-tunable biomaterials to emulate in vivo extracellular matrix environments,with an emphasis on their application in neural repair and regeneration,along with a discussion of the current limitations and future prospects.The exploration and optimization of the stiffness-tunable biomaterials has the potential to markedly advance the development of neural tissue engineering.

原文链接:

万方数据
维普

Pharmacological intervention for chronic phase of spinal cord injury

Chihiro Tohda

1377-1389页

查看更多>>摘要：Spinal cord injury is an intractable traumatic injury.The most common hurdles faced during spinal cord injury are failure of axonal regrowth and reconnection to target sites.These also tend to be the most challenging issues in spinal cord injury.As spinal cord injury progresses to the chronic phase,lost motor and sensory functions are not recovered.Several reasons may be attributed to the failure of recovery from chronic spinal cord injury.These include factors that inhibit axonal growth such as activated astrocytes,chondroitin sulfate proteoglycan,myelin-associated proteins,inflammatory microglia,and fibroblasts that accumulate at lesion sites.Skeletal muscle atrophy due to denervation is another chronic and detrimental spinal cord injury-specific condition.Although several intervention strategies based on multiple outlooks have been attempted for treating spinal cord injury,few approaches have been successful.To treat chronic spinal cord injury,neural cells or tissue substitutes may need to be supplied in the cavity area to enable possible axonal growth.Additionally,stimulating axonal growth activity by extrinsic factors is extremely important and essential for maintaining the remaining host neurons and transplanted neurons.This review focuses on pharmacotherapeutic approaches using small compounds and proteins to enable axonal growth in chronic spinal cord injury.This review presents some of these candidates that have shown promising outcomes in basic research(in vivo animal studies)and clinical trials:AA-NgR(310)ecto-Fc(AXER-204),fasudil,phosphatase and tensin homolog protein antagonist peptide 4,chondroitinase ABC,intracellular sigma peptide,(-)-epigallocatechin gallate,matrine,acteoside,pyrvate kinase M2,diosgenin,granulocyte-colony stimulating factor,and fampridine-sustained release.Although the current situation suggests that drug-based therapies to recover function in chronic spinal cord injury are limited,potential candidates have been identified through basic research,and these candidates may be subjects of clinical studies in the future.Moreover,cocktail therapy comprising drugs with varied underlying mechanisms may be effective in treating the refractory status of chronic spinal cord injury.

原文链接: